Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-transplant cyclophosphamide for graft-versus-host disease prevention after matched allogeneic transplant
ACTRN12613001154796Phase 2Not yet recruiting
- Sponsor
- Westmead Hospital
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cyclophosphamide in graft-versus-host disease (GVHD) and hematopoietic malignancies (2 arms), sponsored by Westmead Hospital. Primary endpoint: Acute graft-versus-host disease grade III-IV rate. Planned start Mar 2014; status: not yet recruiting.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)hematopoietic malignancies
Beyond the preview
Go deeper on ACTRN12613001154796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613001154796.